Celcuity to Hold Conference Call to Discuss Results for the PIK3CA Mutant Cohort of the Phase 3 VIKTORIA-1 Clinical Trial of Gedatolisib Regimens in HR+/HER- Advanced Breast Cancer on June 2, 2026

Rhea-AI Summary

Celcuity (Nasdaq: CELC) will host a conference call and live webcast on June 2, 2026 to discuss results from the PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 clinical trial in HR+/HER2- advanced breast cancer.

The event begins at 8:00 a.m. EDT / 7:00 a.m. CDT, with a replay available on Celcuity's website.

News Market Reaction – CELC

-7.47%

20 alerts

-7.47% Session close to close

-29.6% Trough in 20 hr 41 min

$6.09B Market Cap

1.4x Rel. Volume

In the Jun 1 session, CELC declined 7.47%, reflecting a notable negative market reaction. Argus tracked a trough of -29.6% from its starting point during tracking. Our momentum scanner triggered 20 alerts that day, indicating elevated trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -7.5% in the session following this news. A negative reaction despite this results-f...

Analysis

The stock moved -7.5% in the session following this news. A negative reaction despite this results-focused call would contrast with earlier positive responses to VIKTORIA-1 milestones, including the +15.38% move on May 1, 2026. Weakness could reflect concerns about how detailed PIK3CA mutant data compare to prior topline disclosures or about future funding needs under the $400M ATM shelf. Past news such as simple scheduling releases saw declines, like -6.26% on May 7, 2026, underscoring event-risk sensitivity.

Key Figures

Trial phase: Phase 3 Conference call date: June 2, 2026 Conference call time: 8:00 a.m. EDT / 7:00 a.m. CDT

3 metrics

Trial phase Phase 3 VIKTORIA-1 clinical trial of gedatolisib regimens

Conference call date June 2, 2026 Scheduled webcast to review PIK3CA mutant cohort results

Conference call time 8:00 a.m. EDT / 7:00 a.m. CDT Start time for results discussion call

Previous Conferences,clinical trial Reports

1 past event · Latest: Sep 22 (Positive)

Same Type Pattern 1 events

Date	Event	Sentiment	24h Move	Catalyst
Sep 22	Conference presentation	Positive	+1.2%	Announcement of late-breaking Phase 3 VIKTORIA-1 data presentation at ESMO 2025.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

For similar conferences/clinical-trial presentations, CELC has historically seen modest positive reactions around the event.

Recent Company History

Over recent months Celcuity has steadily built the VIKTORIA program story. On May 1, 2026, positive topline Phase 3 VIKTORIA-1 PIK3CA mutant data drove a 15.38% move. Subsequent earnings on May 14, 2026 highlighted Phase 3 progress, a Priority Review NDA, and strong cash of $387.1M. The current call to discuss PIK3CA mutant cohort results on June 2, 2026 follows this trajectory of increasingly detailed clinical disclosures, similar to prior conference-oriented updates.

Key Terms

PIK3CA, Phase 3, HR+/HER2-

3 terms

PIK3CA medical

"review results from the PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 clinical trial"

PIK3CA is a gene that helps control cell growth and survival by sending signals inside cells; when it carries certain mutations, those signals can become stuck in the “on” position and drive cancer growth. For investors, PIK3CA matters because its mutations are a biomarker used to identify patients for targeted drugs and diagnostics, affecting clinical trial design, approval chances, and potential market size for therapies aimed at those mutations.

Phase 3 medical

"mutant cohort of the Phase 3 VIKTORIA-1 clinical trial on Tuesday, June 2, 2026"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

HR+/HER2- medical

"gedatolisib regimens in HR+/HER2- advanced breast cancer on June 2, 2026"

A cancer subtype where tumor cells have hormone receptors for estrogen and/or progesterone (HR+) but lack excess HER2 protein (HER2−). Think of receptors as locks: HR+ tumors have locks that can be targeted by hormone-blocking drugs, while HER2− means a different lock is absent, so HER2-targeted medicines won’t work. For investors this classification matters because it determines which therapies are appropriate, how large the patient market is, and which clinical trials and regulatory paths are relevant.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MINNEAPOLIS, June 01, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications, today announced it will host a conference call and live webcast to review results from the PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 clinical trial on Tuesday, June 2, 2026 at 8:00 a.m. EDT / 7:00 a.m. CDT.

Webcast and Conference Call Information

The Celcuity management team will host a live webcast and conference call on Tuesday, June 2, 2026, at 8:00 a.m. EDT / 7:00 a.m. CDT to discuss the results from the Phase 3 VIKTORIA-1 trial. Those who would like to participate may access the live webcast here, or register in advance for the teleconference here. A replay of the webcast will be available on the Celcuity website.

About Celcuity

Celcuity is a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications. Our lead therapeutic candidate is gedatolisib, a kinase inhibitor of the PI3K/AKT/mTOR (“PAM”) pathway that binds to all class I PI3K isoforms and the mTOR complexes, mTORC1 and mTORC2. By targeting all class I PI3K isoforms and mTORC1/2, gedatolisib induces comprehensive inhibition of the PAM pathway. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3Kα, AKT, or mTORC1 alone or together. Our Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) (“HR+/HER2-”) locally advanced or metastatic breast cancer (“ABC”), has reported detailed results for Study 1, which evaluated patients with PIK3CA wild-type (“WT”) tumors, and announced topline results for Study 2, which evaluated patients with PIK3CA mutant-type (“MT”) tumors. Our Phase 3 clinical trial, VIKTORIA-2, is ongoing and incorporates two independent studies, Study 1 and Study 2, evaluating two separate cohorts of patients with advanced breast cancer who are treatment-naive in the advanced setting. Study 1 is evaluating gedatolisib combined with palbociclib and fulvestrant as first-line treatment for patients with endocrine-resistant HR+/HER2- ABC. Study 2 is evaluating gedatolisib combined with palbociclib and letrozole as first-line treatment for patients with endocrine-sensitive HR+/HER2- ABC. A Phase 1b/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration-resistant prostate cancer, is ongoing. More detailed information about Celcuity’s active clinical trials can be found at ClinicalTrials.gov. Celcuity is headquartered in Minneapolis, Minnesota. Further information about the Company can be found at www.celcuity.com. Follow us on LinkedIn and X.

Contacts: 

Celcuity Inc. 
Brian Sullivan, bsullivan@celcuity.com
Vicky Hahne, vhahne@celcuity.com  
(763) 392-0123  
Jodi Sievers, jsievers@celcuity.com
(415) 494-9924

FAQ

When is Celcuity's (CELC) VIKTORIA-1 Phase 3 results conference call?

Celcuity will hold its VIKTORIA-1 Phase 3 results conference call on June 2, 2026 at 8:00 a.m. EDT / 7:00 a.m. CDT. According to Celcuity, the call will review data from the PIK3CA mutant cohort.

What trial results will Celcuity (CELC) discuss on June 2, 2026?

Celcuity will discuss results from the PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 trial in HR+/HER2- advanced breast cancer. According to Celcuity, management will review these findings during a live conference call and webcast.

How can investors access Celcuity's June 2, 2026 VIKTORIA-1 webcast?

Investors can access Celcuity's June 2, 2026 webcast through a live online stream or by registering for the teleconference. According to Celcuity, links for live access and advance registration are provided, with a replay available on the company website.

Will a replay of Celcuity's (CELC) VIKTORIA-1 results call be available?

Yes, a replay of Celcuity's VIKTORIA-1 results webcast will be available on the company website after the event. According to Celcuity, the replay will allow investors to review the June 2, 2026 discussion on the PIK3CA mutant cohort.

What is the focus of Celcuity's VIKTORIA-1 Phase 3 trial discussed on June 2, 2026?

The VIKTORIA-1 Phase 3 trial focuses on gedatolisib regimens in HR+/HER2- advanced breast cancer, including a PIK3CA mutant cohort. According to Celcuity, the June 2, 2026 call will specifically review results for this PIK3CA mutant patient group.